[ESMO] Targeting 안전한 바카라 사이트 Resistance…LigaChem Biosciences’ post-Enhertu move with LCB14

[by Ji, Yong Jun] "The success of Enhertu, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in the early-stage breast cancer treatment market underscores the potential competitiveness of LigaChem Biosciences' (hereafter referred to as LCB) drug candidate aimed at treatment-resistant patients."

Lee Dong-gun, Senior Manager at LCB, spoke with <THE BIO on October 20 (local time) during the European Society for Medical Oncology (ESMO 2025) Congress held in Berlin, Germany. At the event, LCB presented two poster sessions featuring its candidate compounds designed to target Enhertu and P안전한 바카라 사이트ev, two 안전한 바카라 사이트s that have fueled the global surge of interest in 안전한 바카라 사이트 therapeutics.

One of the posters featured LCB14 (development code IKS014), a HER2-targeting 안전한 바카라 사이트 candidate developed by Iksuda Therapeutics (hereinafter referred to as Iksuda), a partner of LCB. The other poster introduced LN4305 (topoisomerase I payload) and LN4311 (MMAE payload), both Nectin-4-targeting 안전한 바카라 사이트 candidates that LCB is co-developing with Nectin Therapeutics.

The results of studies on 안전한 바카라 사이트 treatment presented at ESMO emerged as one of the biggest topics of discussion this year. At the congress, Enhertu demonstrated its potential to become a new standard of care in early-stage breast cancer, while P안전한 바카라 사이트ev presented data showing improved overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC). Enhertu is a HER2-targeting 안전한 바카라 사이트 co-developed by AstraZeneca and Daiichi Sankyo, whereas P안전한 바카라 사이트ev is a Nectin-4-targeting 안전한 바카라 사이트 developed by Pfizer and Astellas Pharma.

"Enhertu's expansion into the early-stage breast cancer treatment space, as presented at this year's ESMO, represents a major milestone that underscores the potential of 안전한 바카라 사이트s to penetrate the frontline treatment market. Consequently, there will be a natural rise in demand for new HER2-targeting 안전한 바카라 사이트s among patients who develop resistance or experience poor response to Enhertu," Lee said.

Iksuda's IKS014, a HER2-targeting 안전한 바카라 사이트 that employs LCB’s ConjuALL linker-payload conjugation technology and incorporates monomethyl auristatin F (MMAF, a microtubule formation inhibitor), demonstrated strong potential as a post-Enhertu treatment option. According to the poster, IKS014 achieved an objective response rate (ORR) of 64% (7/11) overall and 43% (3/7) in patients with HER2-low-expressing breast cancer. Notably, three out of four patients who had previously shown no response to Enhertu exhibited a partial response (PR), highlighting the drug’s potential to enter the ‘post-Enhertu’ therapeutic landscape.

In terms of safety, IKS014 demonstrated a favorable tolerability profile, with most adverse events (AEs) being mild and classified as Grade 1 or 2. Serious drug-related adverse events (SAEs) were reported in 8.1% of patients, and only a single case (1.6%) of Grade 3 or higher ocular toxicity was observed.

In the Part 2 expansion phase of the LCB14 clinical trial, Iksuda plans to broaden enrollment to include patients with HER2-positive breast cancer, HER2-low-expressing breast cancer, HER2-positive gastric or gastroesophageal junction cancer, and HER2-mutated non-small cell lung cancer (NSCLC) who have previously been treated with Enhertu.

"In the Part 2 cohort, we will primarily focus on recruiting patients with HER2-positive breast cancer who have previously been treated with Enhertu. For the other cohorts, we plan to conduct a comprehensive assessment of clinical efficacy and safety by including a wider population of patients exhibiting various levels of HER2 expression," Lee stated.

Furthermore, preclinical studies on LN4305 and LN4311 have attracted considerable attention. Both are 안전한 바카라 사이트 candidates currently under development that employ the same antibody backbone but differ in their payloads (monomethyl auristatin E (MMAE) and topoisomerase I), and their competing drug is considered P안전한 바카라 사이트ev.

LN4305 and LN4311 demonstrated durable tumor reduction and, in some cases, complete remission (CR) following a single administration in a refractory relapse model previously treated with P안전한 바카라 사이트ev. Sustained tumor suppression was also observed in models of triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). "We plan to determine the optimal combination based on market dynamics and emerging data or advance into clinical trials through parallel development," Lee remarked.

LCB has taken particular note of the continued expansion of the 안전한 바카라 사이트 market. "Each year, new cancer types are being introduced at academic conferences," Lee said. "Efficacy data are emerging for cancer types that were previously unexplored, clearly illustrating the ongoing growth of the 안전한 바카라 사이트 market," he added.

LCB anticipates the initiation of clinical trials for multiple pipelines beginning next year. "Once our proprietary clinical pipeline is fully unveiled next year, we will be able to clearly demonstrate our platform's competitiveness and its adaptability to the evolving 안전한 바카라 사이트 market," Lee emphasized.